U.S. CDC Advisers Do Not Vote On Whether To Recommend RSV Vaccine For Adults Aged 50 To 59
Portfolio Pulse from Benzinga Newsdesk
U.S. CDC advisers did not vote on whether to recommend the RSV vaccine for adults aged 50 to 59.
June 26, 2024 | 7:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The CDC's decision not to vote on recommending the RSV vaccine for adults aged 50 to 59 could delay potential market expansion for Moderna's RSV vaccine.
Moderna is developing an RSV vaccine, and the CDC's decision not to vote on the recommendation could delay its market entry and potential revenue from this age group.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Pfizer may face delays in expanding the market for its RSV vaccine due to the CDC's decision not to vote on recommending it for adults aged 50 to 59.
Pfizer, which is also developing an RSV vaccine, may experience delays in market expansion and revenue growth due to the CDC's decision not to vote on the recommendation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80